Lexeo Therapeutics has agreed to acquire Mantle Therapeutics via an upfront payment of $8.3 million, aiming to expand its Friedreich ataxia (FA) portfolio while locking in three strategic collaborations to support its lead asset.
Lexeo Therapeutics has agreed to acquire Mantle Therapeutics via an upfront payment of $8.3 million, aiming to expand its Friedreich ataxia (FA) portfolio while locking in three strategic collaborations to...
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
Lexeo Therapeutics has agreed to acquire Mantle Therapeutics via an upfront payment of $8.3 million, aiming to expand its Friedreich ataxia (FA) portfolio while locking in three strategic collaborations to support its lead asset.
Open the app view to save this story, compare related coverage, and continue from the same source.